- Home
- ARGX
ARGX
argenx SE
as 11-20-2024 4:00pm EST
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
| Founded: | 2008 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 35.2B | IPO Year: | 2017 |
| Target Price: | $619.79 | AVG Volume (30 days): | 302.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $327.73 - $611.22 | Next Earning Date: | 10-31-2024 |
| Revenue: | $1,908,659,000 | Revenue Growth: | 85.56% |
| Revenue Growth (this year): | 61.99% | Revenue Growth (next year): | 42.48% |
Latest argenx SE News
ARGX Breaking Stock News: Dive into ARGX Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
MT Newswires
a day ago
Sector Update: Health Care
MT Newswires
a day ago
Argenx to Continue Development of Autoimmune Disease Drug After Phase 2/3 Data
GlobeNewswire
a day ago
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
Insider Monkey
3 days ago
Is argenx SE (ARGX) the Best Immunotherapy Stock to Buy Now?
GlobeNewswire
10 days ago
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
Business Wire
10 days ago
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
Zacks
16 days ago
Why Argenx (ARGX) Might be Well Poised for a Surge
Compare ARGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARGX argenx SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.